Press releases

16 September, 2024

Join Abliva for World Mitochondrial Disease Week 2024, September 16 – 22

-The company shares videos each day of the week to raise awareness about mitochondrial disease and to highlight ongoing activities at Abliva- Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage compa ...

30 August, 2024

Regulatory

Amended number of shares and votes in Abliva AB (publ)

Abliva AB (Nasdaq Stockholm: ABLI) today announces that the number of shares and votes in the Company has increased by 262,500,000, as a result of the conversion of a convertible loan announced by the ...

22 August, 2024

Regulatory

Abliva AB Interim Report January – June 2024

FALCON Positioned for Success Following Analysis by Independent Committee ⎮ Strong Safety Profile Confirmed, and Both Primary Endpoints Passed Futility

19 July, 2024

Regulatory

Positive interim analysis in Abliva’s FALCON study triggers convertible loan conversion

Abliva AB (Nasdaq Stockholm: ABLI) a clinical-stage company developing medicines for the treatment of rare and severe primary mitochondrial disease, today announced that the convertible loan of SEK 42 ...

18 July, 2024

Regulatory

Abliva Announces Positive Interim Analysis of the FALCON Study for KL1333 in Primary Mitochondrial Disease

-Independent committee confirms FALCON study is powered for potential success with both alternative endpoints passing futility- -Committee confirms strong safety profile of KL1333- -Abliva to hos ...

31 May, 2024

Regulatory

Amended number of shares and votes in Abliva AB (publ)

Abliva AB (Nasdaq Stockholm: ABLI) today announces that the number of shares and votes in the Company has increased by 103,149,954, as a result of a preferential rights issue announced by the Board of ...

30 May, 2024

Abliva Announces Completion of 24 Weeks of Dosing in Wave 1 of the FALCON Study of KL1333 in Primary Mitochondrial Disease

-With 24 weeks of dosing complete, Abliva remains on track to report the interim analysis in early Q3 2024- Abliva AB (Nasdaq Stockholm: ABLI) a clinical-stage company developing medicines for [&helli ...

23 May, 2024

Regulatory

Resolutions from Annual General Meeting in Abliva AB (publ) on May 23, 2024

Abliva AB (Nasdaq Stockholm: ABLI) (”Abliva” or the ”Company”) today on May 23, 2024, held its Annual General Meeting (“AGM”). A summary of the resolution follows.

23 May, 2024

Regulatory

Abliva AB Interim Report January – March 2024

SEK 46 million raised through preferential rights issue | Preparations for the interim analysis ongoing

13 May, 2024

Abliva to Host Virtual KOL Event on KL1333 in Primary Mitochondrial Disease on May 21, 2024

Lund, Sweden, May 13, 2024 — Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage company developing drugs for the treatment of rare and severe primary mitochondrial disease, today announced that it w ...

30 April, 2024

Regulatory

Amended number of shares and votes in Abliva AB (publ)

Abliva AB (Nasdaq Stockholm: ABLI) today announces that the number of shares and votes in the Company has increased by 189,935,417, as a result of a preferential rights issue announced by the Board of ...

25 April, 2024

Regulatory

Abliva resolves on a directed issue of shares to guarantors in connection with the completed rights issue

Abliva AB (Nasdaq Stockholm: ABLI) ("Abliva" or the "Company") has today, based on the authorization from the extraordinary general meeting on 26 March 2024, resolved on a directed issue of 5,003,783 ...